GlassScriptPhysician profile
Amarjit S Atwal
NPI 1356346795
$5,434.86
in general payments reported to CMS, 2019-2025
23 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,508 · 2020: $247 · 2021: $418 · 2022: $333 · 2023: $1,179 · 2024: $271 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,670.80 | 2019-2025 | Centurion, Unity, Hydrus Microstent |
| Johnson & Johnson Surgical Vision, INC. | $416.30 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $414.93 | 2019-2021 | |
| Glaukos Corporation | $356.62 | 2025 | Idosetr, Istent, Istent Infinite |
| Rxsight INC | $324.10 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Aerie Pharmaceuticals, INC. | $209.58 | 2019-2021 | |
| Abbott Laboratories | $133.08 | 2023 | Octrode |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Ivantis, INC | $120.97 | 2020-2021 | |
| Allergan, INC. | $120.07 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $111.01 | 2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $106.58 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $83.06 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $48.38 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $33.31 | 2022-2024 | Tyrvaya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $27.91 | 2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $24.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.16 | 2022 | |
| Shire North American Group INC | $18.84 | 2019 | |
| Ocular Therapeutix, INC. | $17.93 | 2024 | Dextenza |
| Sight Sciences, INC. | $17.64 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Kala Pharmaceuticals, INC. | $16.03 | 2019 | |
| Abbvie INC. | $14.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amarjit Atwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.